Two individuals with potential monkeypox virus reinfection
- PMID: 37031694
- PMCID: PMC10079276
- DOI: 10.1016/S1473-3099(23)00185-8
Two individuals with potential monkeypox virus reinfection
Conflict of interest statement
DC has received research grants from Gilead Sciences and GlaxoSmithKline and received payment for educational events and support for attending meetings from Merck Sharp & Dohme and ViiV Healthcare. AC has received personal fees for advisory boards, speaker panels, and educational materials from Gilead Sciences, ViiV Healthcare, Janssen-Cilag, Merck Sharp & Dohme, and Theratechnologies. SN has received personal fees for advisory boards, speaker panels, and educational materials from Gilead Sciences, ViiV Healthcare, Janssen-Cilag, and Merck Sharp & Dohme. All other authors declare no competing interests. Individuals included in the study signed written informed consent to include case details, personal information, and images in the published version of the manuscript in all formats.
Figures
Comment in
-
A tale of potential mpox reinfection.Lancet Infect Dis. 2023 May;23(5):509. doi: 10.1016/S1473-3099(23)00219-0. Epub 2023 Apr 6. Lancet Infect Dis. 2023. PMID: 37031695 Free PMC article. No abstract available.
References
-
- Thornhill JP, Barkati S, Walmsley S, et al. Monkeypox virus infection in humans across 16 countries—April–June 2022. N Engl J Med. 2022;387:679–691. - PubMed
-
- Edghill-Smith Y, Golding H, Manischewitz J, et al. Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus. Nat Med. 2005;11:740–747. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
